

ICMJE DISCLOSURE FORM

Date: 5/6/2026

Your Name: Lyndal Henden

Manuscript Title: Characterising the motif composition and allele length distribution of ZFHX3 GGC repeat expansions in amyotrophic lateral sclerosis

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td>Click the tab key to add additional rows.</td></tr> </table>						Click the tab key to add additional rows.
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
3	Royalties or licenses	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ None <table border="1"> <tr> <td>Biogen</td> <td>Advisory board or consultancies (DBR)</td> </tr> <tr> <td>Celosia Therapeutics</td> <td>Advisory board or consultancies (DBR)</td> </tr> <tr> <td>Genetic signatures</td> <td>Advisory board or consultancies (DBR)</td> </tr> </table>		Biogen	Advisory board or consultancies (DBR)	Celosia Therapeutics	Advisory board or consultancies (DBR)	Genetic signatures	Advisory board or consultancies (DBR)		
Biogen	Advisory board or consultancies (DBR)										
Celosia Therapeutics	Advisory board or consultancies (DBR)										
Genetic signatures	Advisory board or consultancies (DBR)										
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
11	Stock or stock options	☒ None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
13	Other financial or non-financial interests	☐ None <table border="1" style="width: 100%; margin-top: 5px;"> <tr> <td>Biogen</td> <td>Sponsored research agreement (JHV)</td> </tr> <tr> <td>Eli Lilly</td> <td>Sponsored research agreement (JHV)</td> </tr> <tr> <td>Trace</td> <td>Sponsored research agreement (JHV)</td> </tr> <tr> <td>Astra Zeneca</td> <td>Sponsored research agreement (JHV)</td> </tr> </table>		Biogen	Sponsored research agreement (JHV)	Eli Lilly	Sponsored research agreement (JHV)	Trace	Sponsored research agreement (JHV)	Astra Zeneca	Sponsored research agreement (JHV)
Biogen	Sponsored research agreement (JHV)										
Eli Lilly	Sponsored research agreement (JHV)										
Trace	Sponsored research agreement (JHV)										
Astra Zeneca	Sponsored research agreement (JHV)										

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.